Nikki Borman Image

Nikki Borman

CEO and Founder

Borman & Company

Nikki Borman is the CEO and founder of Borman & Company, a consulting firm that helps research-intensive institutions advance effective technology transfer through every step along the path to commercialization. Nikki has an extensive track record of developing and implementing enhanced business models, workflows, financial structure, and regulatory reporting for leading academic institutions and medical research centers.

Prior to founding Borman & Company in 2007, Nikki worked in tech transfer and licensing at MIT and Brandeis University and put in her time providing advisory services at three of the big four: Ernest & Young, KPMG Advisory and PwC.

Nikki has been tasked as a peer reviewer for the DOD congressionally directed medical research programs and has served in various capacities for AUTM (Association of University Technology Managers) where she spearheaded the Better World Report.


Recent Articles by Nikki Borman

U.S Manufacturing Requirement Changes the Landscape for Bayh-Dole Compliance Reporting

In recent months, two U.S. government executive initiatives have reshaped the landscape concerning intellectual property and the domestic production of products resulting from federally funded research. These initiatives are poised to bring substantial changes to the dynamics of academic-industry collaborations as inventions are brought to market.

The IP Challenge for Medical Research Centers

As we scan the press attention around medical intellectual property (IP) during these pandemic times, an impassioned debate centers on whether there should be a reprieve on patent rights for COVID-19 vaccines. This threat to longstanding agreements and investment in public/private sector partnerships undermines not only the ownership of IP but also sets a dangerous precedent in terms of downstream consequences. An additional challenge to patents owned by academic medical centers and pharmaceutical companies is posed by activist groups that are lobbying our government to exercise march-in rights to influence pricing of medicines in the United States. Working with medical research centers around Bayh-Dole Act compliance has uncovered, time after time, a more systemic risk that eats away at the health of the research portfolio and could add fuel to the fire for diluting IP protection, thereby undermining the foundation of innovation.